Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

121.57 +0.16 (+0.13%)
Official Closing Price Updated: 4:10 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,899,459
Open 122.36
Bid (Size) 121.17 (600)
Ask (Size) 122.00 (300)
Prev. Close 121.41
Today's Range 120.80 - 123.08
52wk Range 73.31 - 123.33
Shares Outstanding 2,531,374,696
Dividend Yield 2.80%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗
The comments come as ImmunityBio pushes for broader global access to Anktiva across indications. 
Via Stocktwits

Performance

YTD
+14.2%
+14.2%
1 Month
+11.1%
+11.1%
3 Month
+30.9%
+30.9%
6 Month
+44.3%
+44.3%
1 Year
+46.0%
+46.0%

More News

Read More
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
News headline image
8 Cheap Stocks to Buy in 2026 ↗
Via The Motley Fool
News headline image
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
Via The Motley Fool
Topics Stocks
News headline image
Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
Via MarketMinute
Topics Earnings
News headline image
Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗
Via The Motley Fool
News headline image
Dow Jones 267-Point Slide: Blue-Chip Leaders and the AI Reality Check
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
3 Mega-Cap Stocks for Long-Term Investors
Via StockStory
Topics Supply Chain
News headline image
The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
From Merck & Co., Inc.
Via Business Wire
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Via Finterra
Topics Economy Intellectual Property
News headline image
5 Revealing Analyst Questions From Merck’s Q4 Earnings Call
Via StockStory
Topics Earnings Intellectual Property
News headline image
Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗
Via The Motley Fool
Topics Economy Intellectual Property Stocks
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal
Via MarketMinute
Topics Economy Government Immigration
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
Via Finterra
Topics Economy Government Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 121.57
When was Merck & Co last traded?
The last trade of Merck & Co was at 02/17/26 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 307.74B
How many shares of Merck & Co are outstanding?
Merck & Co has 308B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.